MAI Capital Management Acquires 607 Shares of Edwards Lifesciences Corporation $EW

MAI Capital Management raised its holdings in shares of Edwards Lifesciences Corporation (NYSE:EW) by 0.7% during the second quarter, according to its most recent filing with the SEC. The firm owned 86,534 shares of the medical research company’s stock after purchasing an additional 607 shares during the period. MAI Capital Management’s holdings in Edwards Lifesciences were worth $6,768,000 at the end of the most recent reporting period.

Several other large investors have also modified their holdings of EW. Quantbot Technologies LP bought a new position in shares of Edwards Lifesciences during the first quarter valued at approximately $26,000. SouthState Corp purchased a new stake in Edwards Lifesciences during the first quarter worth $27,000. Rosenberg Matthew Hamilton purchased a new stake in Edwards Lifesciences during the second quarter worth $28,000. Costello Asset Management INC bought a new stake in Edwards Lifesciences during the 1st quarter valued at $29,000. Finally, NewSquare Capital LLC increased its holdings in shares of Edwards Lifesciences by 57.8% in the 2nd quarter. NewSquare Capital LLC now owns 366 shares of the medical research company’s stock valued at $29,000 after acquiring an additional 134 shares during the period. Institutional investors own 79.46% of the company’s stock.

Analysts Set New Price Targets

A number of equities research analysts recently weighed in on EW shares. National Bankshares set a $92.00 price objective on Edwards Lifesciences in a research note on Friday, October 31st. Piper Sandler reiterated an “overweight” rating and issued a $95.00 target price (up from $90.00) on shares of Edwards Lifesciences in a report on Friday, October 31st. UBS Group restated a “neutral” rating and issued a $90.00 price target on shares of Edwards Lifesciences in a report on Monday, November 3rd. The Goldman Sachs Group set a $104.00 price objective on shares of Edwards Lifesciences and gave the stock a “buy” rating in a research report on Friday, October 31st. Finally, Canaccord Genuity Group reissued a “hold” rating and set a $84.00 target price (up previously from $81.00) on shares of Edwards Lifesciences in a research report on Monday, November 3rd. Three research analysts have rated the stock with a Strong Buy rating, fourteen have assigned a Buy rating, ten have given a Hold rating and one has given a Sell rating to the company. According to MarketBeat.com, Edwards Lifesciences has a consensus rating of “Moderate Buy” and an average target price of $91.39.

Insider Activity

In related news, VP Daniel J. Lippis sold 1,020 shares of the stock in a transaction that occurred on Monday, November 10th. The shares were sold at an average price of $82.55, for a total value of $84,201.00. Following the transaction, the vice president owned 22,002 shares in the company, valued at approximately $1,816,265.10. This represents a 4.43% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, CFO Scott B. Ullem sold 13,000 shares of the firm’s stock in a transaction that occurred on Monday, November 10th. The stock was sold at an average price of $83.08, for a total transaction of $1,080,040.00. Following the transaction, the chief financial officer directly owned 39,898 shares of the company’s stock, valued at $3,314,725.84. This represents a 24.58% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Company insiders own 1.29% of the company’s stock.

Edwards Lifesciences Trading Up 1.1%

NYSE:EW opened at $85.02 on Friday. The company has a market capitalization of $49.34 billion, a P/E ratio of 12.23, a PEG ratio of 3.97 and a beta of 1.03. The company has a current ratio of 4.68, a quick ratio of 3.87 and a debt-to-equity ratio of 0.06. Edwards Lifesciences Corporation has a 12 month low of $65.94 and a 12 month high of $87.21. The firm has a fifty day simple moving average of $78.80 and a 200-day simple moving average of $78.07.

Edwards Lifesciences (NYSE:EW) last released its earnings results on Thursday, October 30th. The medical research company reported $0.67 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.59 by $0.08. Edwards Lifesciences had a return on equity of 15.01% and a net margin of 72.96%.The firm had revenue of $1.55 billion for the quarter, compared to the consensus estimate of $1.49 billion. During the same period in the prior year, the firm earned $0.67 EPS. The firm’s revenue was up 14.7% on a year-over-year basis. Edwards Lifesciences has set its FY 2025 guidance at 2.560-2.620 EPS. Q4 2025 guidance at 0.580-0.640 EPS. On average, equities research analysts anticipate that Edwards Lifesciences Corporation will post 2.45 earnings per share for the current year.

About Edwards Lifesciences

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.